000283114 001__ 283114
000283114 005__ 20260103103703.0
000283114 0247_ $$2doi$$a10.1002/alz70861_108724
000283114 0247_ $$2ISSN$$a1552-5260
000283114 0247_ $$2ISSN$$a1552-5279
000283114 037__ $$aDZNE-2026-00010
000283114 082__ $$a610
000283114 1001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b0$$eFirst author$$udzne
000283114 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283114 245__ $$aAnti‐oligomeric PRI‐002 does not cause ARIA‐E in an ongoing Phase 2 trial
000283114 260__ $$c2025
000283114 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767354807_32511
000283114 3367_ $$033$$2EndNote$$aConference Paper
000283114 3367_ $$2BibTeX$$aINPROCEEDINGS
000283114 3367_ $$2DRIVER$$aconferenceObject
000283114 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283114 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283114 3367_ $$2ORCID$$aOTHER
000283114 520__ $$aBackgroundAmyloid related imaging abnormalities (ARIA) are a common side effect of monoclonal anti-amyloid antibodies and limit the benefit risk ratio. Here we investigate the safety and efficacy of the anti-oligomeric all-D-peptide PRI-002 in early AD. PRI-002 is an orally available, first in class compound developed to disassemble neurotoxic Aβ oligomers into non-toxic Aβ monomers. In a phase 1 B study PRI-002 has been shown to improve learning and memory function in early AD patients after 4 weeks of once-daily oral treatment and 4 weeks follow-up (Kutzsche et al., Nat. Commun. 2025).MethodPRImus-AD (NCT06182085) is an ongoing randomized, double-blind, placebo-controlled phase 2 study of PRI-002 in early symptomatic AD receiving either 300 mg, 600 mg or placebo every day for at least 48 weeks. Safety is measured by comparing adverse and serious adverse events in verum groups versus placebo. Primary efficacy outcome is CDR-SB. According to study protocol intense MRI monitoring to detect possible ARIA-E were performed during titration.Result304 patients 70.4±6.5 years on age, with a MMSE of 25.2±2.2, 155 with MCI (51.0%) and 149 (49.0%) with mild dementia were randomized. CDR-SB at baseline was 3.3±1.4 and RBANS-DMI 54.8±12.7. 208 patients have at least one APOE4 allele (68.4%). After 90 patients, irrespective of the treatment arm, had passed the first 24 weeks of treatment, the incidence of ARIA was evaluated. Within these 90 patients ARIA-E occurred in 4 (4.4%) and ARIA-H were detected in 13 (14.4%) subjects. This incidence is in line with large observational cohorts like ADNI. An unblinded DSMB reviewed the ARIA incidence in all three study arms and recommended to stop the intense ARIA monitoring for the rest of the study, since no imbalance was detected.ConclusionIn an ongoing phase 2 trial with oral PRI-002 that was designed to disassemble synaptotoxic Aβ aggregates into harmless Aβ monomers, the study drug is safe and in detail does not cause ARIA incidents Efficacy data are expected in 2026.
000283114 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283114 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283114 7001_ $$aJürgens, Dagmar$$b1
000283114 7001_ $$aTischler, Gerhard$$b2
000283114 7001_ $$aBrener, Alexander$$b3
000283114 7001_ $$aBartsch, Tina$$b4
000283114 7001_ $$aKauselmann, Gunther$$b5
000283114 7001_ $$aAdermann, Knut$$b6
000283114 7001_ $$aZeiger, Kathrin$$b7
000283114 7001_ $$aLindner, Katja$$b8
000283114 7001_ $$aGabelich, Julie-Anne$$b9
000283114 7001_ $$aWillbold, Dieter$$b10
000283114 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70861_108724$$gVol. 21, no. S7, p. e108724$$nS7$$pe108724$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283114 8564_ $$uhttps://pub.dzne.de/record/283114/files/DZNE-2026-00010.pdf$$yOpenAccess
000283114 8564_ $$uhttps://pub.dzne.de/record/283114/files/DZNE-2026-00010.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283114 909CO $$ooai:pub.dzne.de:283114$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283114 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811024$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283114 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283114 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283114 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283114 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283114 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283114 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283114 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283114 9201_ $$0I:(DE-2719)5000000$$kAG Peters$$lBiomarker-Assisted Early Detection of Dementias$$x0
000283114 980__ $$aabstract
000283114 980__ $$aVDB
000283114 980__ $$aUNRESTRICTED
000283114 980__ $$ajournal
000283114 980__ $$aI:(DE-2719)5000000
000283114 9801_ $$aFullTexts